Breakthrough Progress: P2X3 Receptor Antagonist Offers New Hope for Chronic Cough Patients

Hansoh Pharma Announces Significant Results of HS-10383, a Highly Selective P2X3 Receptor Antagonist, in Phase 1 Clinical Trial for Refractory or Unexplained Chronic Cough (RUCC)And debuted at the Asia-Pacific Respiratory Society Conference (APSR 2024) held in Hong Kong, China.Brings New Treatment Hope for Patients with Chronic Cough Worldwide.

1. HS-10383: Hansoh Pharma's Breakthrough Research Results

HS-10383 is a P2X3 receptor antagonist independently developed by Hansoh Pharma for RUCC. With its high selectivity, the drug aims to provide patients with a safe and effective treatment option. Currently, HS-10383 has entered Phase 2 clinical trials to evaluate its efficacy, safety, and tolerability at different doses.

2. Positive Results of Phase 1 Clinical Trial

Hansoh Pharma Presents First-in-Human Phase 1 Data for HS-10383 at APSR 2024

3. Challenges in RUCC Treatment and the Application of P2X3 Receptor Antagonists

Refractory or Unexplained Chronic Cough (RUCC) is a condition that significantly impacts patients' quality of life, affecting approximately 10% of adults worldwide. Currently, the treatment of RUCC primarily focuses on symptom management, with a lack of effective long-term therapeutic options. P2X3 receptor antagonists, as a novel treatment approach, are considered a potential drug for RUCC.

P2X3 receptors are widely expressed in the nervous and respiratory systems and are closely related to diseases such as chronic cough. Inhibition of P2X3 receptors can reduce afferent nerve excitability, thereby alleviating cough symptoms.

4. Global Research and Development Progress of P2X3 Receptor Antagonists

Currently, several P2X3 receptor antagonists have entered the development stage globally, among which Merck's Gefapixant has been approved in Japan and the European Union. A 2023 study published in the *Journal of the American Medical Association* indicated that Gefapixant significantly reduces the cough frequency and severity in patients with RUCC, improving their quality of life.

Hansoh Pharma's HS-10383 and Bayer's Eliapixant, among other investigational drugs, also show promising prospects. Results from the Phase 1 clinical study of Eliapixant indicate that the drug has good tolerability and a low incidence of taste-related adverse events.

5. Conclusion

The positive results of Hansoh Pharma's HS-10383 in Phase 1 clinical trials have brought new hope to patients with chronic cough. As P2X3 receptor antagonists continue to advance in clinical research, we have reason to believe that more effective treatment options will be provided for millions of chronic cough patients worldwide in the future. We look forward to HS-10383 continuing to demonstrate its excellent efficacy and safety in subsequent clinical trials, bringing more benefits to patients.